Only in the past decade tremendous advances have been made in understanding prostate cancer genomics and consequently in applying new treatment strategies. As options regarding treatments are increasing so are the challenges in selecting the right treatment option for each patient and not the least, understanding the optimal time-point and sequence of applying available treatments. Critically, without reliable methods that enable sequential monitoring of evolving genotypes in individual patients, we will never reach effective personalised driven treatment approaches. This review focuses on the clinical implications of prostate cancer genomics and the potential of cfDNA in facilitating treatment management.

仅在过去的十年中，在了解前列腺癌基因组学以及因此应用新的治疗策略方面取得了巨大的进步。随着有关治疗选择的增加，为每个患者选择正确的治疗选择的挑战也越来越多，要了解应用可用治疗的最佳时间点和顺序，这一点同样重要。至关重要的是，如果没有可靠的方法能够对每个患者的基因型进行连续监测，我们将永远无法找到有效的个性化驱动治疗方法。这篇综述集中在前列腺癌基因组学的临床意义以及cfDNA在促进治疗管理中的潜力。